Guggenheim analyst Yatin Suneja downgrades RAPT Therapeutics (NASDAQ:RAPT) from Buy to Neutral.
Guggenheim Downgrades RAPT Therapeutics to Neutral
The above content is for informational or educational purposes only and does not constitute any investment advice related to Futu. Although we strive to ensure the truthfulness, accuracy, and originality of all such content, we cannot guarantee it.